Vittoria Biotherapeutics reported the first patient was dosed in VIPER-101's Phase 1 trial for T-cell lymphoma. VIPER-101 is a gene-edited, autologous dual-population CAR-T therapy using the Senza5 platform, which features CD5 modulation and a five-day manufacturing process.
Keith Westby joined Vittoria Biotherapeutics as its inaugural chief operating officer. The company describes him as having more than two decades of biotechnology entrepreneurial experience.
Vittoria Biotherapeutics announced a Science Immunology publication by University of Pennsylvania investigators about the influence of CD5, an immunomodulatory protein.
The page discusses the potential and limitations of CAR T-cell therapy and Vittoria's focus on developing immunotherapies for difficult-to-treat diseases.
Vittoria Biotherapeutics says it will not request sensitive personal information, such as Social Security numbers, dates of birth, or bank account details, through email, job recruiting, or social media.
Vittoria Biotherapeutics is a clinical-stage company with the Senza5 platform, which powers a pipeline of immunotherapies designed to address unmet clinical needs in oncology and immunology.
